We evaluated the use of immunohistochemistry (IHC) for detection of epidermal growth factor receptor (EGFR) mutations in nonesmall-cell lung cancer on a cohort of 79 EGFR-mutated Whites. IHC demonstrated high accuracy for detection of common EGFR mutations as well as for predicting response to ...
Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early dissemination, development of chemoresistance and a poor prognosis. A host of diverse drugs failed invariably and its mechanisms of global chemoresistance have not been characterized so far. SCLC represents the...
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expression. Circulating-tumor-cell-derived explant models (CDX...
Lung cancer is the most common cause of cancer death, and small cell lung cancer (SCLC) represents approximately 15% of all cases [1]. Despite remarkable progress in the treatment of non-small cell lung cancer in the last decade [2], patients with SCLC continue to have a poor prognosis ...
C/EBP{alpha} expression by immunohistochemistry lacks prognostic or predictive significance in primary resected non-small cell lung cancer C/EBP{alpha} expression by immunohistochemistry lacks prognostic or predictive significance in primary resected non-small cell lung cancer... DB Costa,P Stephenson,O...
Lung cancer is the leading cause of cancer death worldwide. Lung cancers are mainly of two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Small cell lung cancer accounts for about 15% of all the types of lung cancers. The SCLC is also known as small cel...
Jianbing Huang, Yuanyuan Lei, Xinfeng Wang, Chengming Liu, Nan Sun* and Jie He* Abstract Background: Angiogenesis, a basic requirement for tumor cell survival, is considered to be a malignant characteristic of small cell lung cancer (SCLC) and is closely related to the poor outcomes of SCLC...
Small-cell lung cancer (SCLC) is speculated to harbor complex genomic intratumor heterogeneity (ITH) associated with high recurrence rate and suboptimal response to immunotherapy. Here, using multi-region whole exome/T cell receptor (TCR) sequencing as well as immunohistochemistry, we reveal a rather...
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune checkpoint blockade have been initiate
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:203–8. 33. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for ...